Cargando…

Statistical analysis of PML incidences of natalizumab-treated patients from 2009 to 2016: outcomes after introduction of the Stratify JCV® DxSelect™ antibody assay

Detalles Bibliográficos
Autores principales:	Campagnolo, Denise, Dong, Qunming, Lee, Lily, Ho, Pei-Ran, Amarante, Diogo, Koendgen, Harold
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2016
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5127882/ https://www.ncbi.nlm.nih.gov/pubmed/27730447 http://dx.doi.org/10.1007/s13365-016-0482-z

Ejemplares similares

Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values
por: Schwab, Nicholas, et al.
Publicado: (2016)

Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation
por: Iannetta, Marco, et al.
Publicado: (2016)

Treatment of natalizumab‐associated PML with filgrastim
por: Stefoski, Dusan, et al.
Publicado: (2019)

High rates of JCV seroconversion in a large international cohort of natalizumab-treated patients
por: Dwyer, Christopher M., et al.
Publicado: (2021)

Improving risk‐stratification of natalizumab‐associated PML
por: Tugemann, Bastian, et al.
Publicado: (2021)

Rising JCV-Ab index during natalizumab therapy for MS: Inauspicious for a highly efficacious drug
por: Javed, Adil, et al.
Publicado: (2016)

Severe early natalizumab-associated PML in MS: Effective control of PML-IRIS with maraviroc
por: Bsteh, Gabriel, et al.
Publicado: (2017)

Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab
por: Antoniol, Caroline, et al.
Publicado: (2015)

Concomitant granule cell neuronopathy in patients with natalizumab-associated PML
por: Wijburg, Martijn T., et al.
Publicado: (2016)

PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation
por: Killestein, J., et al.
Publicado: (2014)

Outcome and survival of asymptomatic PML in natalizumab-treated MS patients
por: Dong-Si, Tuan, et al.
Publicado: (2014)

Pathologic Findings of Chronic PML-IRIS in a Patient with Prolonged PML Survival Following Natalizumab Treatment
por: Himedan, Mai, et al.
Publicado: (2017)

Dynamic changes of MMP-9 plasma levels correlate with JCV reactivation and immune activation in natalizumab-treated multiple sclerosis patients
por: Iannetta, Marco, et al.
Publicado: (2019)

Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities
por: Honce, Justin M., et al.
Publicado: (2015)

Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS
por: Hodecker, Sibylle C., et al.
Publicado: (2017)

Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcome
por: Maillart, Elisabeth, et al.
Publicado: (2017)

Sequencing and Analysis of JC Virus DNA From Natalizumab-Treated PML Patients
por: Reid, Carl E., et al.
Publicado: (2011)

Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus
por: Werner, Milton H., et al.
Publicado: (2016)

High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study
por: Malucchi, Simona, et al.
Publicado: (2016)

Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing
por: Ryerson, Lana Zhovtis, et al.
Publicado: (2019)

New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab
por: Toboso, Inmaculada, et al.
Publicado: (2020)

Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab
por: Fissolo, Nicolás, et al.
Publicado: (2021)

Maraviroc in PML-IRIS: A separate ball game under HIV infection and natalizumab?
por: Steiner, Israel, et al.
Publicado: (2017)

Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients
por: Plavina, Tatiana, et al.
Publicado: (2017)

A link between long-term natalizumab dosing in MS and PML: Putting the puzzle together
por: Major, Eugene O., et al.
Publicado: (2016)

7T MRI in natalizumab-associated PML and ongoing MS disease activity: A case study
por: Sinnecker, Tim, et al.
Publicado: (2015)

Metabolic profiles by (1)H-magnetic resonance spectroscopy in natalizumab-associated post-PML lesions of multiple sclerosis patients who survived progressive multifocal leukoencephalopathy (PML)
por: Schneider, Ruth, et al.
Publicado: (2017)

CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients
por: Lieberman, Linda A., et al.
Publicado: (2016)

Natalizumab-induced POU2AF1/Spi-B upregulation: A possible route for PML development
por: Meira, Maria, et al.
Publicado: (2016)

Progressive multifocal leukoencephalopathy: MRI findings in HIV-infected patients are closer to rituximab- than natalizumab-associated PML
por: Alleg, Manel, et al.
Publicado: (2020)

Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experiment
por: Muñoz-Vendrell, Albert, et al.
Publicado: (2023)

Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
por: Perumal, Jai, et al.
Publicado: (2021)

Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
por: Perumal, Jai, et al.
Publicado: (2021)

JC Polyomavirus (JCV) and Monoclonal Antibodies: Friends or Potential Foes?
por: Diotti, Roberta Antonia, et al.
Publicado: (2013)

JCV seroconversion rate during the SARS COVID-19 pandemic
por: Vigiser, I., et al.
Publicado: (2022)

Bag3-Induced Autophagy Is Associated with Degradation of JCV Oncoprotein, T-Ag
por: Sariyer, Ilker Kudret, et al.
Publicado: (2012)

No detection of EBV, BKV and JCV in breast cancer tissue samples in Iran
por: Dowran, Razieh, et al.
Publicado: (2019)

Anti-JCV antibody index does not change during ocrelizumab-treatment
por: Rempe, Torge, et al.
Publicado: (2020)

Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study
por: Kappos, Ludwig, et al.
Publicado: (2017)

Primary bilateral adrenal B-cell lymphoma associated with EBV and JCV infection
por: Barzon, Luisa, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_240sb8ehn8dj7qblgnv3gbenji